BIOTEST AG (BIO.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BIO - DE0005227201 - Common Stock
42.2 EUR
-0.4 (-0.94%)
BIO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 82 industry peers in the Biotechnology industry. BIO has an average financial health and profitability rating. BIO has a valuation in line with the averages, but on the other hand it scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year BIO has reported negative net income.
BIO had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: BIO reported negative net income in multiple years.
In multiple years BIO reported negative operating cash flow during the last 5 years.
1.2 Ratios
BIO has a better Return On Assets (-1.73%) than 66.67% of its industry peers.
BIO's Return On Equity of -4.81% is fine compared to the rest of the industry. BIO outperforms 68.06% of its industry peers.
Looking at the Return On Invested Capital, with a value of 0.54%, BIO is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.73% | ||
| ROE | -4.81% | ||
| ROIC | 0.54% |
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
BIO has a better Operating Margin (1.87%) than 75.00% of its industry peers.
BIO's Operating Margin has improved in the last couple of years.
BIO has a Gross Margin (23.19%) which is comparable to the rest of the industry.
BIO's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.87% | ||
| PM (TTM) | N/A | ||
| GM | 23.19% |
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO is destroying value.
BIO has about the same amout of shares outstanding than it did 1 year ago.
BIO has about the same amout of shares outstanding than it did 5 years ago.
BIO has a better debt/assets ratio than last year.
2.2 Solvency
BIO has an Altman-Z score of 2.36. This is not the best score and indicates that BIO is in the grey zone with still only limited risk for bankruptcy at the moment.
BIO has a better Altman-Z score (2.36) than 70.83% of its industry peers.
BIO has a debt to FCF ratio of 46.44. This is a negative value and a sign of low solvency as BIO would need 46.44 years to pay back of all of its debts.
BIO's Debt to FCF ratio of 46.44 is fine compared to the rest of the industry. BIO outperforms 76.39% of its industry peers.
A Debt/Equity ratio of 1.26 is on the high side and indicates that BIO has dependencies on debt financing.
With a Debt to Equity ratio value of 1.26, BIO perfoms like the industry average, outperforming 40.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | 46.44 | ||
| Altman-Z | 2.36 |
ROIC/WACC0.09
WACC6.01%
2.3 Liquidity
BIO has a Current Ratio of 4.93. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
BIO has a Current ratio of 4.93. This is amongst the best in the industry. BIO outperforms 81.94% of its industry peers.
BIO has a Quick Ratio of 1.66. This is a normal value and indicates that BIO is financially healthy and should not expect problems in meeting its short term obligations.
BIO has a Quick ratio (1.66) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.93 | ||
| Quick Ratio | 1.66 |
3. Growth
3.1 Past
BIO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.24%.
Looking at the last year, BIO shows a very negative growth in Revenue. The Revenue has decreased by -15.85% in the last year.
Measured over the past years, BIO shows a quite strong growth in Revenue. The Revenue has been growing by 11.62% on average per year.
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BIO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 27.85, the valuation of BIO can be described as expensive.
80.56% of the companies in the same industry are more expensive than BIO, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of BIO to the average of the S&P500 Index (23.93), we can say BIO is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.85 |
4.2 Price Multiples
72.22% of the companies in the same industry are more expensive than BIO, based on the Enterprise Value to EBITDA ratio.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of BIO indicates a somewhat cheap valuation: BIO is cheaper than 77.78% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 115.96 | ||
| EV/EBITDA | 43.06 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
With a yearly dividend of 0.09%, BIO is not a good candidate for dividend investing.
BIO's Dividend Yield is rather good when compared to the industry average which is at 0.80. BIO pays more dividend than 90.28% of the companies in the same industry.
With a Dividend Yield of 0.09, BIO pays less dividend than the S&P500 average, which is at 1.87.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.09% |
5.2 History
On average, the dividend of BIO grows each year by 14.87%, which is quite nice.
Dividend Growth(5Y)14.87%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
The dividend of BIO is growing, but earnings are growing more, so the dividend growth is sustainable.
DPN/A
EPS Next 2YN/A
EPS Next 3YN/A
FRA:BIO (6/6/2025, 7:00:00 PM)
42.2
-0.4 (-0.94%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners0.21%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.67B
Revenue(TTM)635.20M
Net Income(TTM)-24.50M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.09% |
Yearly Dividend0.04
Dividend Growth(5Y)14.87%
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 27.85 | ||
| P/S | 2.63 | ||
| P/FCF | 115.96 | ||
| P/OCF | 115.96 | ||
| P/B | 3.28 | ||
| P/tB | 3.39 | ||
| EV/EBITDA | 43.06 |
EPS(TTM)-0.65
EYN/A
EPS(NY)1.52
Fwd EY3.59%
FCF(TTM)0.36
FCFY0.86%
OCF(TTM)0.36
OCFY0.86%
SpS16.05
BVpS12.88
TBVpS12.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.73% | ||
| ROE | -4.81% | ||
| ROCE | 0.95% | ||
| ROIC | 0.54% | ||
| ROICexc | 0.56% | ||
| ROICexgc | 0.57% | ||
| OM | 1.87% | ||
| PM (TTM) | N/A | ||
| GM | 23.19% | ||
| FCFM | 2.27% |
ROA(3y)2.71%
ROA(5y)-0.12%
ROE(3y)7.23%
ROE(5y)-0.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y111.24%
ROICexc growth 3YN/A
ROICexc growth 5Y111.29%
OM growth 3YN/A
OM growth 5Y99.04%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y25.34%
GM growth 5Y0.06%
F-Score3
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | 46.44 | ||
| Debt/EBITDA | 12.19 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 0.82 | ||
| Cash Conversion | 27.43% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.93 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 2.36 |
F-Score3
WACC6.01%
ROIC/WACC0.09
Cap/Depr(3y)81.86%
Cap/Depr(5y)79.06%
Cap/Sales(3y)4.84%
Cap/Sales(5y)4.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.24%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-173.33%
EPS Next Y1600%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-15.85%
Revenue growth 3Y12.09%
Revenue growth 5Y11.62%
Sales Q2Q%-42.29%
Revenue Next Year11.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-93.3%
EBIT growth 3YN/A
EBIT growth 5Y122.17%
EBIT Next Year825%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y114.72%
FCF growth 3Y27.05%
FCF growth 5YN/A
OCF growth 1Y114.72%
OCF growth 3Y21.56%
OCF growth 5YN/A
BIOTEST AG / BIO.DE FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.DE.
What is the valuation status of BIOTEST AG (BIO.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to BIOTEST AG (BIO.DE). This can be considered as Fairly Valued.
What is the profitability of BIO stock?
BIOTEST AG (BIO.DE) has a profitability rating of 4 / 10.
What is the expected EPS growth for BIOTEST AG (BIO.DE) stock?
The Earnings per Share (EPS) of BIOTEST AG (BIO.DE) is expected to grow by 1600% in the next year.